- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT02417740
Historia naturalna nadciśnienia wrotnego bez marskości wątroby
Background:
- Noncirrhotic Portal Hypertension (NCPH) is caused by liver diseases that increase pressure in the blood vessels of the liver. It seems to start slowly and not have many warning signs. Many people may not even know that they have a liver disease. There are no specific treatments for NCPH.
Objectives:
- To learn more about how NCPH develops over time.
Eligibility:
- People age 12 and older who have NCPH or are at risk for getting it. In the past year, they cannot have had other types of liver disease that typically result in cirrhosis, liver cancer, or active substance abuse.
Design:
- Participants will have 2 screening visits.
- Visit 1: to see if they have or may develop NCPH.
- Medical history
- Physical exam
- Urine and stool studies
- Abdominal ultrasound
- Fibroscan. Sound waves measure liver stiffness.
<TAB>- Visit 2:
- Blood tests
- Abdominal MRI
- Echocardiogram
- Questionnaire
- Liver blood vessel pressure (hepatic venous portal gradient (HVPG)) measurement. This is done with a small tube inserted in a neck vein.
- They may have a liver biopsy.
- All participants will visit the clinic every 6 months for a history, physical exam, and blood tests. They will also repeat some of the screening tests yearly.
- Participants with NCPH will also have:
- Upper endoscopy test. A tube inserted in the mouth goes through the esophagus and stomach.
- At least every 2 years: Esophagogastroduodenoscopy.
- At least every 4 years: testing including HVPG measurements and liver biopsy.
- Participants without NCPH will also have:
- Liver biopsy and HVPG measurements to see if they have NCPH.
- Every 2 years: abdominal MRI and stool studies.
- The study will last indefinitely.
Przegląd badań
Status
Szczegółowy opis
Study Description:
Up to 400 subjects with noncirrhotic portal hypertension or at risk for developing noncirrhotic portal hypertension by virtue of their
underlying disease (as well as sporadic cases of noncirrhotic portal hypertension as referred to in this protocol) will be offered inclusion
in the study.
Objectives:
Primary Objective:
1. The goal of this natural history study is to generate understanding of the development and progression of NCPH. We will use our
findings to generate novel biomarkers that will enable improved follow-up of patients, assist in preventing complications, and
enhance transplant decision.
Secondary Objectives:
- Measurement of the bile acids and lipids to understand NCPH and porto-systemic shunting.
- Identification of the genetic modifiers of NCPH.
- Evaluation of hepatic transcriptome in absence and presence of NCPH.
- Characterization of microbiome signatures in NCPH.
Endpoints:
Primary Endpoints:
- Establish surveillance methods and guidelines for evaluation of NCPH.
- Develop an understanding of the biological mechanisms of the progression of NCPH.
- Identification of novel biomarkers correlating with NCPH progression.
Secondary Endpoints:
- Measurement of bile acids fractionated and total, as well as lipid panel to establish cut-off levels correlating with NCPH severity.
- Establishment of positive or negative correlation between candidate susceptible genes and disease phenotype.
- Identification of novel markers of fibrosis or the development of hepatic neoplasia from transcriptome analysis.
- Characterization of microbiome signatures (taxonomic and functional), as well as identification of specific species.
Typ studiów
Zapisy (Szacowany)
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Theo Heller, M.D.
- Numer telefonu: (301) 402-7147
- E-mail: theoh@intra.niddk.nih.gov
Kopia zapasowa kontaktu do badania
- Nazwa: Jaha F Norman-Wheeler
- Numer telefonu: (301) 435-6122
- E-mail: jaha.norman-wheeler@nih.gov
Lokalizacje studiów
-
-
Maryland
-
Bethesda, Maryland, Stany Zjednoczone, 20892
- Rekrutacyjny
- National Institutes of Health Clinical Center
-
Kontakt:
- Jaha Norman-Wheeler
- Numer telefonu: 301-435-6122
- E-mail: jaha.norman-wheeler@nih.gov
-
Kontakt:
- For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
- Numer telefonu: TTY dial 711 (800) 411-1222
- E-mail: ccopr@nih.gov
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Subjects with diagnosis of noncirrhotic portal hypertension above age of 12 years
Opis
- INCLUSION CRITERIA:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Male or female, aged >= 18 years of age, and minors 12-17 years of age.
- Women of childbearing potential must agree to use birth control unless they are menopausal or had hysterectomy.
- Known diagnosis of NCPH, or to be at the risk for NCPH by virtue of underlying disease processes such as but not limited to; CGD, SCD, Mastocytosis, CVID, CF, and CHF.
EXCLUSION CRITERIA:
An individual who meets any of the following criteria will be excluded from participation in this study:
- Pregnancy.
- Evidence of other forms of liver disease that typically result in cirrhosis.
- Evidence of active Chronic Hepatitis B infection as defined by the presence of hepatitis B surface antigen (HBsAg) in serum and elevated HBV DNA (>10,000 IU/mL).
- Hepatitis C as defined by the presence of hepatitis C RNA in serum.
- Evidence of other liver disease such as primary sclerosing cholangitis, primary biliary cirrhosis, Wilson s disease, autoimmune hepatitis as defined by either liver histology or laboratory abnormalities.
- Hemochromatosis as defined by presence of 3+ or 4+ stainable iron on liver biopsy or homozygosity for C282Y. Patients with iron saturation indices of >45% and serum ferritin levels of >300 ng/ml for men and >250 ng/ml for women will undergo genetic testing for hemochromatosis.
- Bile duct obstruction as suggested by imaging studies done within the previous six months.
- The presence of cirrhosis confirmed by liver biopsy.
- Active substance abuse, such as alcohol, inhaled or injection drugs within the previous one year (assessed during subject interviews by subject self-report).
- Evidence of hepatocellular carcinoma; either alpha-fetoprotein (AFP) levels greater than 50 ng/ml (normal <6.6ng/ml) and/or ultrasound (or other imaging study) demonstrating a mass suggestive of liver cancer.
- Evidence of cholangiocarcinoma as suggested by liver histology.
- Any other severe condition, which in the opinion of the investigators would impede the patient s participation or compliance in the study.
- Inability to comply or give written informed consent.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: COHORT
- Perspektywy czasowe: PROSPECTIVE
Kohorty i interwencje
Grupa / Kohorta |
|---|
|
Adult with absence of Portal Hypertension
Confirmed absence of Portal Hypertension will have no findings suggestive of non cirrhotic portal hypertension on liver biopsy and on portal pressure measurements on confirmatory examination. |
|
Adult with presence of Portal Hypertension
Confirmed Presence of Noncirrhotic Portal Hypertension, through confirmatory testing, tissue diagnosis by liver biopsy and/or portal hypertension (HVPG >5mmHg). |
|
Minors likely to have the absence of Portal Hypertension
Minors identified as Confirmed Absence of Noncirrhotic Portal Hypertension will have no abnormal findings on confirmatory examination. |
|
Minors likely to have the presence of Portal Hypertension
Minors identified as Confirmed Presence of Noncirrhotic Portal Hypertension, have shown they have the disease with a tissue diagnosis by liver biopsy and/or portal hypertension (HVPG >5). |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
To study the natural history of non cirrhotic portal hypertension. It is an ongoing study.
Ramy czasowe: Ongoing
|
natural history study |
Ongoing
|
Współpracownicy i badacze
Śledczy
- Główny śledczy: Theo Heller, M.D., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Publikacje i pomocne linki
Publikacje ogólne
- Sarin SK, Aggarwal SR. Idiopathic portal hypertension. Digestion. 1998 Jul-Aug;59(4):420-3. doi: 10.1159/000007502. No abstract available.
- Sarin SK, Kumar A, Chawla YK, Baijal SS, Dhiman RK, Jafri W, Lesmana LA, Guha Mazumder D, Omata M, Qureshi H, Raza RM, Sahni P, Sakhuja P, Salih M, Santra A, Sharma BC, Sharma P, Shiha G, Sollano J; Members of the APASL Working Party on Portal Hypertension. Noncirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and treatment. Hepatol Int. 2007 Sep;1(3):398-413. doi: 10.1007/s12072-007-9010-9. Epub 2007 Sep 11.
- Schouten JN, Garcia-Pagan JC, Valla DC, Janssen HL. Idiopathic noncirrhotic portal hypertension. Hepatology. 2011 Sep 2;54(3):1071-81. doi: 10.1002/hep.24422. Epub 2011 Jul 21.
Przydatne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Szacowany)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby układu moczowo-płciowego
- Choroby układu hormonalnego
- Choroby naczyniowe
- Choroby układu krążenia
- Choroby układu moczowo-płciowego u mężczyzn
- Stany patologiczne, anatomiczne
- Choroby układu moczowo-płciowego kobiet
- Choroby układu moczowo-płciowego kobiet i powikłania ciąży
- Choroby serca
- Choroby genetyczne, wrodzone
- Choroby układu odpornościowego
- Choroby Układu Oddechowego
- Choroby Układu Pokarmowego
- Choroby płuc
- Niemowlę, noworodek, choroby
- Choroby trzustki
- Zaburzenia gonad
- Wady wrodzone
- Nieprawidłowości sercowo-naczyniowe
- Wady serca, wrodzone
- Zaburzenia rozwoju płciowego
- Zaburzenia układu moczowo-płciowego
- Zaburzenia chromosomów płciowych
- Zaburzenia chromosomowe
- Zaburzenia chromosomów płciowych rozwoju płci
- Hipertrofia
- Dysgenezja gonad
- Wrodzone, dziedziczne i noworodkowe choroby i nieprawidłowości
- Stany patologiczne, oznaki i objawy
- Idiopatyczne nadciśnienie wrotne bez marskości wątroby
- Choroby wątroby
- Zespoły niedoboru odporności
- Nadciśnienie, portal
- Mukowiscydoza
- Żylaki
- Zespół Turnera
- Splenomegalia
- Zwłóknienie wątroby, wrodzone
Inne numery identyfikacyjne badania
- 150108
- 15-DK-0108
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
This is a longitudinal study and it is not yet known if and when IPD will be made available.
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .